Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 7% – Time to Sell?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) dropped 7% during trading on Tuesday. The stock traded as low as $21.60 and last traded at $21.6310. 178,281 shares changed hands during trading, a decline of 26% from the average daily volume of 240,852 shares. The stock had previously closed at $23.25.

Analysts Set New Price Targets

A number of analysts have recently weighed in on FTH shares. BTIG Research restated a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Wall Street Zen lowered shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Needham & Company LLC began coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They set a “buy” rating and a $56.00 target price for the company. Finally, Raymond James Financial assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Stock Up 5.0%

The business’s 50 day moving average price is $31.58. The firm has a market cap of $542.41 million, a P/E ratio of -0.15 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. Equities research analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the last quarter. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the first quarter valued at about $4,188,000. Finally, Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the first quarter valued at about $22,758,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.